Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness

Cover Page

Cite item

Full Text

Abstract

Differentiated thyroid cancer is one of the most common malignant diseases of the endocrine system. Usually, it responds well to the standard treatment (surgery + radioiodine therapy), especially at early stages. During both treatment and dynamic observation, distant metastases are detected in 10–15 % of patients. In these cases, the patients continue treatment with radioactive iodine. If tumor cells have insufficient ability to capture and retain 131I or completely lose this ability, the effect of radioiodine therapy becomes limited and the disease progresses during therapy which leads to 5–10 % decrease in 10-year survival. The main problem in treatment of differentiated thyroid cancer is communication between radiologists in centers performing radioiodine therapy and clinical oncologists performing surgeries and observation at patient’s place of residence. For both specialists, the main goal is to identify clinical situations where early and effective treatment intervention can be beneficial without the risk of overdiagnosis and excessive treatment.

The article considers common questions arising during multidisciplinary interactions with radiologists of radioiodine centers and presents concise guidelines on the observation and treatment procedures for patients with differentiated thyroid cancer.

About the authors

E. V. Borodavina

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Author for correspondence.
Email: smysmymrik2007@yandex.ru
ORCID iD: 0000-0002-3306-5906

Ekaterina vladimirovna Borodavina

4 Koroleva St., Obninsk 249036

Russian Federation

S.  I. Kutukova

City Clinical Oncological Dispensary; I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-2221-4088

1 Malaya Sadovaya St., Saint Petersburg 191023; 6–8, L’va Tolstogo St., Saint Petersburg 197022

Russian Federation

A. Yu. Shurinov

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-4934-2012

4 Koroleva St., Obninsk 249036

Russian Federation

E. B. Vasil’eva

Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Email: fake@neicon.ru
ORCID iD: 0000-0003-1285-2182

42 Blukhera St., Chelyabinsk 454087

Russian Federation

A. O. Guz

Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Email: fake@neicon.ru
ORCID iD: 0000-0002-8164-2261

42 Blukhera St., Chelyabinsk 454087

Russian Federation

I. V. Grishkevich

Sverdlovsk Regional Oncological Dispensary

Email: fake@neicon.ru

29 Soboleva St., Ekaterinburg 620036

Russian Federation

S. D. Karateeva

Perm Regional Oncological Dispensary

Email: fake@neicon.ru

15 Baumana St., Perm 614066

Russian Federation

A. R. Shakhmatova

Research Institute of Clinical Oncology, Nizhny Novgorod Regional Clinical Oncological Dispensary

Email: fake@neicon.ru

11/1 Delovaya St., Nizhny Novgorod 603093

Russian Federation

R. S. Slobodyanskiy

Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Email: fake@neicon.ru

42 Blukhera St., Chelyabinsk 454087

Russian Federation

O. V. Romanchuk

Center of Outpatient Oncological Care, Moscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare Department

Email: fake@neicon.ru

8 Sosensky Stan St., Kommunarka, Moscow 108814

Russian Federation

M. R. Mukhitova

Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after prof. M.Z. Sigal

Email: fake@neicon.ru
ORCID iD: 0000-0002-0741-624X

29 Sibirskiy Trakt St., Kazan 420029

Russian Federation

M. P. Karpovich

Center of Outpatient Oncological Care, Moscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare Department

Email: fake@neicon.ru

8 Sosensky Stan St., Kommunarka, Moscow 108814

Russian Federation

S. P. Dmitriev

Research Institute of Clinical Oncology, Nizhny Novgorod Regional Clinical Oncological Dispensary

Email: fake@neicon.ru

11/1 Delovaya St., Nizhny Novgorod 603093

Russian Federation

O. S. Saypeeva

Perm Regional Oncological Dispensary

Email: fake@neicon.ru

15 Baumana St., Perm 614066

Russian Federation

K. A. Tolpeykina

Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Email: fake@neicon.ru
ORCID iD: 0000-0002-0864-6493

42 Blukhera St., Chelyabinsk 454087

Russian Federation

S. S. Tolstov

Tambov Regional Oncological Clinical Dispensary

Email: fake@neicon.ru

29B Moskovskaya St., Tambov 392000

Russian Federation

A. V. Makarova

Ivanovo Regional Oncological Dispensary

Email: fake@neicon.ru

5 Lyubimova St., Ivanovo 153040

Russian Federation

Ya. A. Tyugina

Ivanovo Regional Oncological Dispensary

Email: fake@neicon.ru

5 Lyubimova St., Ivanovo 153040

Russian Federation

E. G. Ovchinnikova

Research Institute of Clinical Oncology, Nizhny Novgorod Regional Clinical Oncological Dispensary

Email: fake@neicon.ru

11/1 Delovaya St., Nizhny Novgorod 603093

Russian Federation

References

  1. Rumyantsev P.O., Fomin D.K., Rumyantseva U.V. Criteria of well-differentiated thyroid carcinoma resistance to radioiodine therapy. Opukholi golovy i shei = Head and Neck Tumors 2014;(3):4–9. (In Russ.). doi: 10.17650/2222-1468-2014-0-3-4-9
  2. Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary andfollicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9. doi: 10.1210/jc.2005-2838
  3. Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9. doi: 10.1210/jc.2005-1322
  4. Shurinov A.Yu., Borodavina E.V., Krylov V.V. et al. Guidelines for radioiodine therapy in differentiated thyroid cancer and posttherapeutic follow-up. Opukholi golovy i shei = Head and Neck Tumors 2024;14(1):83–95. (In Russ.). doi: 10.17650/2222-1468-2024-14-1-83-95
  5. Choinzonov E.L., Reshetov I.V., Ivanov S.A. et al. Draft of clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients. Endokrinnaya khirurgiya = Endocrine Surgery 2022;16(2):5–29. (In Russ.). doi: 10.14341/serg12792
  6. Haugen B., Alexander E., Bible Keith C. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133. doi: 10.1089/thy.2015.0020
  7. Shurinov A.Yu., Borodavina E.V. Follow-up after radioiodine remnant ablation in differentiated thyroid cancer: the view of nuclear medicine physician. Opukholi golovy i shei = Head and Neck Tumors 2023;13(1):91–101. (In Russ.). doi: 10.17650/2222-1468-2023-13-1-91-101
  8. Biondi B., Cooper D.S. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010;20(2):135–46. doi: 10.1089/thy.2009.0311
  9. Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. doi: 10.1016/j.ejca.2008.10.026
  10. Bolotina L.V., Vladimirova L.Yu., Dengina N.V. et al. Practical guidelines on drug treatment of head and neck tumors. RUSSCO practical guidelines, part 1. Zlokachestvennie opukholi = Malignant Tumors 2023;13:100–19. (In Russ.).
  11. Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8. doi: 10.1016/S2213-8587(13)70215-8
  12. Berdelou A., Lamartina L., Klain M. et al. Treatment of refractory thyroid cancer. Endocr Relat Cancer 2018;25(4):R209–23. doi: 10.1530/ERC-17-0542
  13. Tuttle R.M., Brose M.S., Grande E. et al. Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2017;31(3):295–305.
  14. Castagna M.G., Maino F., Cipri C. et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011;165(3):441–6. doi: 10.1530/EJE-11-0466
  15. Gruber J.J., Colevas A.D. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 2015;20(2):113–26. doi: 10.1634/theoncologist.2014-0313
  16. Durante C., Attard M., Torlontano M. et al. Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab 2010;95(11):4882–8. doi: 10.1210/jc.2010-0762
  17. Grani G., Lamartina L., Cantisani V. et al. Interobserver agreement of various thyroid imaging reporting and data systems. Endocr Connect 2018;7(1):1–7. doi: 10.1530/EC-17-0336
  18. Lamartina L., Grani G., Biffoni M. et al. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. J Clin Endocrinol Metab 2016;101(8):3036–44. doi: 10.1210/jc.2016-1440
  19. Leenhardt L., Erdogan M.F., Hegedus L. et al. 2013 European Thyroid Association Guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J 2013;2(3):147–59. doi: 10.1159/000354537
  20. Sgouros G., Kolbert K.S., Sheikh A. et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) software. J Nucl Med 2004;45(8):1366–72.
  21. Robbins R.J., Wan Q., Grewal R.K. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxyD-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006. doi: 10.1210/jc.2005-1534
  22. Leboulleux S., El Bez I., Borget I. et al. Post-radioiodine treatment whole body scan in the era of fluorodesoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 2012. doi: 10.1089/thy.2012-0081
  23. NCCN Clinical Practice Guidelines in Oncology Thyroid Carcinoma. Version 4.2023. August 16, 2023. NCCN. Published online 2023. doi: 10.1001/jamaoncol.2018.2706
  24. Taylor M.H., Takahashi S., Capdevila J. et al. Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 2021;31(8):1226–34. doi: 10.1089/thy.2020.0779
  25. Tahara M., Kiyota N., Hoff A.O. et al. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 2021;147:51–7. doi: 10.1016/j.ejca.2020.12.032
  26. Brose M.S., Panaseykin Y., Konda B. et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab 2022;107(3):776–87. doi: 10.1210/clinem/dgab731
  27. Tahara M., Brose M.S., Wirth L.J. et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 2019;106:61–8. doi: 10.1016/j.ejca.2018.10.002

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36990 от  21.07.2009.